Biohaven Ltd. (NYSE:BHVN) Director John W. Childs Purchases 29,000 Shares

Biohaven Ltd. (NYSE:BHVN) Director John W. Childs acquired 29,000 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $35.94 per share, with a total value of $1,042,260.00. Following the purchase, the director now owns 2,368,741 shares of the company’s stock, valued at $85,132,551.54. The trade was a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Biohaven Stock Up 4.4 %

Shares of BHVN opened at $37.35 on Thursday. The company has a market cap of $3.78 billion, a price-to-earnings ratio of -3.99 and a beta of 1.24. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21. The company has a 50 day moving average of $44.71 and a two-hundred day moving average of $42.02.

Biohaven (NYSE:BHVN) last announced its earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). On average, sell-side analysts expect that Biohaven Ltd. will post -8.85 EPS for the current year.

Institutional Investors Weigh In On Biohaven

Institutional investors have recently bought and sold shares of the company. Stifel Financial Corp lifted its stake in shares of Biohaven by 0.4% during the third quarter. Stifel Financial Corp now owns 6,509,261 shares of the company’s stock worth $325,268,000 after buying an additional 28,684 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Biohaven by 5.6% during the third quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company’s stock worth $311,142,000 after buying an additional 328,099 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Biohaven by 181.4% during the second quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock worth $78,028,000 after buying an additional 1,449,000 shares during the period. Geode Capital Management LLC lifted its stake in shares of Biohaven by 2.6% during the third quarter. Geode Capital Management LLC now owns 1,714,612 shares of the company’s stock worth $85,696,000 after buying an additional 44,174 shares during the period. Finally, Point72 Asset Management L.P. lifted its stake in shares of Biohaven by 745.9% during the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock worth $74,969,000 after buying an additional 1,322,922 shares during the period. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on BHVN shares. JPMorgan Chase & Co. raised their target price on shares of Biohaven from $55.00 to $68.00 and gave the stock an “overweight” rating in a research report on Thursday, October 3rd. Leerink Partners raised their target price on shares of Biohaven from $55.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. Jefferies Financial Group started coverage on shares of Biohaven in a research report on Monday, September 16th. They set a “buy” rating and a $57.00 target price on the stock. Robert W. Baird raised their target price on shares of Biohaven from $58.00 to $60.00 and gave the stock an “outperform” rating in a research report on Monday, September 23rd. Finally, Sanford C. Bernstein raised their target price on shares of Biohaven from $55.00 to $66.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 24th. Thirteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $63.00.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.